UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 30, 2017

 

 

Versartis, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-36361   26-4106690

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

4200 Bohannon Drive, Suite 250

Menlo Park, California

  94025
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (650) 963-8580

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Chief Development Officer; Appointment of Chief Medical Officer

On September 5, 2017, Versartis, Inc. (the “ Company ”) announced the appointment of Dr. Robert Gut, M.D., Ph.D., to the position of Chief Medical Officer. On August 30, 2017, Dr. Colin Hislop, M.D., relinquished his duties as Chief Medical Officer, effective September 5, 2017, and will continue leading the Company’s development activities as Chief Development Officer.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: September 6, 2017     Versartis, Inc.
    By:  

/s/ Joshua T. Brumm

      Joshua T. Brumm
      Chief Financial Officer and Chief Operating Officer
VERSARTIS, INC. (NASDAQ:VSAR)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more VERSARTIS, INC. Charts.
VERSARTIS, INC. (NASDAQ:VSAR)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more VERSARTIS, INC. Charts.